01345nas a2200457   4500000000100000000000100001000000100002008004100003653001100044653004400055653003200099653006100131653001100192653001600203653004400219653000900263653000900272653001900281653001400300653000900314653002800323653001000351653000900361653000900370653002900379653002900408653001500437653001900452653002400471100001300495700001600508700001900524700001200543700001400555700001600569245023700585250001500822300001200837490000700849020003100856       2024                            d10aHumans10a*Diabetes Mellitus, Type 2/drug therapy10a*Bisoprolol/therapeutic use10a*Antihypertensive Agents/therapeutic use/adverse effects10aFemale10aMiddle Aged10a*Hypertension/epidemiology/drug therapy10aMale10aAged10aCohort Studies10aIncidence10aBias10aRisk Assessment/methods10aAdult10aCprd10aIpcw10aType 2 diabetes mellitus10aAntihypertensive therapy10abisoprolol10acensoring bias10areal-world evidence1 aA. Pinon1 aA. Allignol1 aT. Hohenberger1 aC. Foch1 aE. Boutmy1 aU. Hostalek00aDependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practice Research Datalink cohort study  a2024/10/17  ae2300270 v13  a2042-6305 (Print)2042-6305